Prosecution Insights
Last updated: November 04, 2026

Mbf Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Mbf Therapeutics Inc. manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and 1 distinct art unit, centralizing the company's current prosecution efforts. This concentration suggests that the company is focusing its resources on a specific therapeutic or biological innovation. The pending office action represents the current state of the company's efforts to secure patent protection in this field.

The busiest examiner for the company is QIAN, CELINE X, who is assigned 1 busiest examiner pending office action. The progress of the company's active docket depends on the specific review and guidance provided by this examiner. For a practitioner, it is important to tailor arguments to the specific preferences of this official within the Biotechnology & Pharmaceuticals art unit. The outcome of the 1 pending office action will determine the company's immediate success in expanding its patent portfolio. Navigating the requirements of this individual examiner is the most critical task for the company's current prosecution strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
QIAN, CELINE X 1 47.5% +17.3%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18064219 ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS QIAN, CELINE X 22d overdue

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18064219 ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS QIAN, CELINE X 22d overdue

Top Art Units

Art UnitApps
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18064219 ENHANCED IMMUNOGENIC DNA/RNA COMPOSITIONS AND METHODS QIAN, CELINE X 1637 §103§112 Final Rejection 22d overdue Pending Dec 09, 2022

Managing Mbf Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mbf Therapeutics Inc. have?

Mbf Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Mbf Therapeutics Inc. applications?

Celine X Qian has the most, with 1 of Mbf Therapeutics Inc.'s pending office actions.

What technology area are Mbf Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month